anti-CD20/CD30-CAR-T / Shanghai First Song Therap - LARVOL DELTA

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Affiliated Hospital of Nantong University

New P1 trial • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Oncology

Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects With Relapsed/Refractory Lymphoma (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: Shanghai First Song Biotechnology Co., LTD

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Lymphoma • Oncology • TNFRSF8